Develops marine-derived bioactive compounds into pharmaceutical drug candidates by building a drug-discovery pipeline that bridges academia and industry. Targets cancers and other high-unmet-need diseases, with a hematology-focused FLT3 inhibitor asset that has passed animal proof-of-concept.